PMID- 35413714
OWN - NLM
STAT- MEDLINE
DCOM- 20220804
LR  - 20220826
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Linking)
VI  - 183
IP  - 8
DP  - 2022
TI  - Clinical Efficacy and Safety of Artesimia annua-Sublingual Immunotherapy in 
      Seasonal Allergic Rhinitis Patients Based on Different Intervention Time.
PG  - 852-859
LID - 10.1159/000524108 [doi]
AB  - INTRODUCTION: Artemisia is a major kind of grass pollen in Northern China that 
      can cause multiple kinds of common allergic diseases, such as allergic rhinitis 
      (AR), conjunctivitis, or asthma. Recently, Artemisia annua Allergens Sublingual 
      Immunotherapy Drops have been proved effective and safe for treating seasonal AR 
      (SAR) with or without allergic conjunctivitis patients and were available in 
      China. We sought to further investigate the different intervention times of A. 
      annua-sublingual immunotherapy (SLIT) for evaluating efficacy and safety in 
      patients with SAR. METHODS: A total of 88 subjects aged 18-52 years with SAR were 
      enrolled and randomized into the SLIT group and control group. Forty-five 
      patients received a course of SLIT with A. annua extracts along with 
      pharmacotherapy as SLIT group and 43 patients only used symptomatic drugs as 
      control group. Furthermore, SLIT group was randomly divided into 12-13 weeks' 
      pre-seasonal treatment group and 8-9 weeks' pre-seasonal treatment group to 
      receive different duration of SLIT before pollen season. Monosensitized and 
      polysensitized groups were also the subgroups of SLIT group according to the 
      sensitization status of patients. The combined symptom and medication score 
      (CSMS), total nasal symptom score (TNSS), total medication score (TMS), visual 
      analog score (VAS) were evaluated during the peak pollen phase in 2020 and 2021, 
      respectively. Safety was assessed according to adverse events (AEs) reported. 
      RESULTS: Compared to control group, CSMS, TNSS, TMS, VAS were significantly 
      improved during the course of SLIT (p < 0.001). Besides, clinical improvement in 
      nasal symptoms and reduction of medication use was also observed in SLIT group, 
      compared to the baseline value (p < 0.001). Meanwhile, we observed that there was 
      no significant difference between monosensitized group (n = 8) and polysensitized 
      group (n = 29), as well as 12-13 weeks' preseasonal treatment group (n = 20) and 
      8-9 weeks' pre-seasonal treatment group (n = 17) belonging to the SLIT group in 
      clinical efficacy (p > 0.05). No severe systemic AEs were reported. CONCLUSIONS: 
      This study proved that A. annua-SLIT can provide equivalent efficacy and safety 
      for SAR patients under the circumstance of accepting the pre-seasonal treatment 
      of 8-9 or 12-13 weeks, regardless of monosensitization or polysensitization.
CI  - (c) 2022 S. Karger AG, Basel.
FAU - Yang, Jiayi
AU  - Yang J
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, China.
FAU - Shen, Zhen
AU  - Shen Z
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, China.
FAU - Liu, Lifeng
AU  - Liu L
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, China.
FAU - Kang, Wei
AU  - Kang W
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, China.
FAU - Shao, Yuan
AU  - Shao Y
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, China.
FAU - Zhang, Pengfei
AU  - Zhang P
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, China.
FAU - Quan, Fang
AU  - Quan F
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220412
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
SB  - IM
MH  - Allergens
MH  - Antigens, Dermatophagoides
MH  - *Artemisia annua/adverse effects
MH  - Humans
MH  - *Rhinitis, Allergic/drug therapy
MH  - *Rhinitis, Allergic, Seasonal/drug therapy
MH  - *Sublingual Immunotherapy/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Artemisia annua
OT  - Efficacy
OT  - Safety
OT  - Seasonal allergic rhinitis
OT  - Sublingual immunotherapy
EDAT- 2022/04/13 06:00
MHDA- 2022/08/05 06:00
CRDT- 2022/04/12 20:16
PHST- 2022/01/20 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/08/05 06:00 [medline]
PHST- 2022/04/12 20:16 [entrez]
AID - 000524108 [pii]
AID - 10.1159/000524108 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2022;183(8):852-859. doi: 10.1159/000524108. Epub 2022 
      Apr 12.